SUNPHARMA - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.2
✅ Positive
Sun Pharma demonstrates robust profit growth with a significant increase in PAT for the current quarter (27% to ₹2,895 Cr.) and an overall upward trend in revenue. The company's strong India growth offsets concerns related to US generics, evidenced by the recent positive earnings report.
⚠️ Limitation
Despite impressive top-line growth, the stock is trading at a high P/E ratio of 150, indicating potential overvaluation. Furthermore, the missed Q1 estimates suggest headwinds in the US market could still impact future performance.
📉 Company Negative News
The company's Q1 earnings were below expectations due to unfavorable trends in the US generics business and lower-than-anticipated sales. This suggests potential margin pressure and increased competition in a key market segment.
📈 Company Positive News
Sun Pharma reported a 10% increase in revenue, indicating strong demand for its products across various geographies. The company's profitability also rose significantly, driven by improved operational efficiencies and strategic initiatives.
🏭 Industry
The pharmaceutical industry is currently experiencing moderate growth, with increasing demand for generic drugs globally. However, intense competition and regulatory scrutiny remain significant challenges for companies in this sector, particularly concerning US market access and pricing pressures.
🧾 Conclusion
Based on the current price of 1,989 ₹, a short-term entry zone could be established between 1,950 ₹ (support level identified by recent lows) and 2,030 ₹ (resistance level near the high). A potential exit strategy would involve selling around 2,060 ₹ if the price encounters significant resistance. The stock appears to be trending upwards with momentum sustained by volume increases.